Loading
NYSEHealthcareBiotechnology
Latest quote
$126.63
+$15.68 · +14.13%
Veradermics, Incorporated functions as a biopharmaceutical enterprise focused on devising pioneering therapeutic interventions for various skin and cosmetic disorders. The company's development pipeline includes treatments for Pattern Hair Loss (PHL), impacting both adult and pediatric demographics. A flagship offering is VDPHL01, an orally administered, non-hormonal medication specifically for chronic hair loss management in both male and female patients with PHL. Furthermore, Veradermics is progressing with VDMN, an innovative dissolvable microarray patch technology employing immunotherapy for common warts. Its research also extends to VDAA for addressing alopecia areata, and VDMC, aimed at molluscum contagiosum. Collectively, the firm's product candidates target conditions such as androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. Veradermics caters to healthcare practitioners and clinicians specializing in dermatologic and aesthetic care for patients of all ages, in addition to the wider medical and scientific community engaged in dermatology. Founded in 2019, the company is based in New Haven, Connecticut.
Latest quote
$126.63
+$15.68 · +14.13%
After-hours
$126
−$0.63 · -0.50%
Oct 8, 7:43 PM ET
Regular session · ET · Market data may be delayed.
Veradermics, Incorporated functions as a biopharmaceutical enterprise focused on devising pioneering therapeutic interventions for various skin and cosmetic disorders. The company's development pipeline includes treatments for Pattern Hair Loss (PHL), impacting both adult and pediatric demographics. A flagship offering is VDPHL01, an orally administered, non-hormonal medication specifically for chronic hair loss management in both male and female patients with PHL. Furthermore, Veradermics is progressing with VDMN, an innovative dissolvable microarray patch technology employing immunotherapy for common warts. Its research also extends to VDAA for addressing alopecia areata, and VDMC, aimed at molluscum contagiosum. Collectively, the firm's product candidates target conditions such as androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. Veradermics caters to healthcare practitioners and clinicians specializing in dermatologic and aesthetic care for patients of all ages, in addition to the wider medical and scientific community engaged in dermatology. Founded in 2019, the company is based in New Haven, Connecticut.
Day range
Current $126.63
52-week range
Current $126.63
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
40
Expensive
Sentiment
58
Mixed
Risk
41
Elevated Risk
Momentum
70
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Veradermics, Incorporated functions as a biopharmaceutical enterprise focused on devising pioneering therapeutic interventions for various skin and cosmetic disorders. The company's development pipeline includes treatments for Pattern Hair Loss (PHL), impacting both adult and pediatric demographics. A flagship offering is VDPHL01, an orally administered, non-hormonal medication specifically for chronic hair loss management in both male and female patients with PHL. Furthermore, Veradermics is progressing with VDMN, an innovative dissolvable microarray patch technology employing immunotherapy for common warts. Its research also extends to VDAA for addressing alopecia areata, and VDMC, aimed at molluscum contagiosum. Collectively, the firm's product candidates target conditions such as androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. Veradermics caters to healthcare practitioners and clinicians specializing in dermatologic and aesthetic care for patients of all ages, in addition to the wider medical and scientific community engaged in dermatology. Founded in 2019, the company is based in New Haven, Connecticut.
Day range
Current $126.63
52-week range
Current $126.63
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Research and development | 62.07M USD | 23.28M USD | 14.97M USD |
| Selling, general, and administrative | 10.28M USD | 3.5M USD | 2.35M USD |
| Operating expenses | 72.35M USD | 26.78M USD | 17.32M USD |
| Interest income | 1.56M USD | 481K USD | 870K USD |
| Interest expense | — | 585K USD | 36K USD |
| Operating income | −72.35M USD | −26.78M USD | −17.32M USD |
| Net income | −70M USD | −26.49M USD | −16.49M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$162.67
28.46% upsideLimited analyst sample: 4 ratings. Interpret the distribution with caution.
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Russell 2000 ETFIWM64.19M0.08%78.56B USD0.19%$277.57-0.05%
Vanguard Morningstar Total Stock Market ETFVTI61M0.00%2.3T USD0.03%$379.56-0.39%
Vanguard Extended Market ETFVXF22.94M0.02%95.4B USD0.05%$233.13-0.15%
JPMorgan Active Growth ETFJGRO19.39M0.19%10.3B USD0.44%$97.41-1.14%
Schwab U.S. Small-Cap ETFSCHA18.32M0.08%21.7B USD0.03%$32.66+0.15%
iShares Russell 2000 Growth ETFIWO15.78M0.11%14.04B USD0.24%$353.47-0.53%
Vanguard Russell 2000 ETFVTWO12.31M0.07%18B USD0.06%$112.1-0.10%
iShares U.S. Pharmaceuticals ETFIHE12.02M0.79%1.53B USD0.37%$98.86-0.53%iShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFJPMorgan Active Growth ETFJGROSchwab U.S. Small-Cap ETFSCHAiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares U.S. Pharmaceuticals ETFIHEAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
